Representation and outcomes for older patients in phase 3 clinical trials for metastatic and unresectable head and neck squamous cell carcinoma (HNSCC): A systematic review. This is an ASCO Meeting ...

Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell ...

CHICAGO – The postoperative addition of nivolumab (Opdivo) to chemoradiotherapy (CRT) extended disease-free survival (DFS) in ...

Adding nivolumab to adjuvant CRT improved DFS in patients with locally advanced head and neck squamous cell carcinoma at high risk of relapse.

Immunotherapies are undoubtedly transforming the landscape of cancer treatment worldwide. By harnessing the body's immune ...

About 40 percent of cancer cases are considered preventable. Try these lifestyle changes to stay healthy.

In the Phase 1/1b trial, ficerafusp alfa in combination with pembrolizumab resulted in deep and durable anti-tumor activity with improved overall survival (OS) compared to historical benchmarks in ...

Head and neck cancer comprises a group of biologically similar cancers that start in the lip, oral cavity (mouth), nasal ... Most head and neck cancers are squamous cell carcinomas that originate ...

Examining age-specific trends in the incidence of human papillomavirus-associated oropharyngeal cancer in the United States. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

NIVOPOSTOP trial data demonstrate a reduction in the risk of recurrence or death with adjuvant nivolumab combined with ...

Classification of immune profiling on tumor samples helps explain improving treatment outcomes, paving the way for ...

Researchers are also investigating the PD-1 immune checkpoint inhibitor as treatment before surgical and radiation treatment.